• Je něco špatně v tomto záznamu ?

HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group

JD. Kowalska, D. Bursa, D. Gökengin, D. Jilich, J. Tomazic, M. Vasylyev, P. Bukovinowa, V. Mulabdic, S. Antonyak, A. Horban, ECEE Network Group,

. 2018 ; 19 (9) : 629-633. [pub] 20180710

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028333
E-zdroje Online Plný text

NLK Free Medical Journals od 1999 do Před 2 roky
Medline Complete (EBSCOhost) od 1999-10-01 do Před 1 rokem
Wiley Free Content od 1999 do Před 2 roky

Odkazy

PubMed 29989332
DOI 10.1111/hiv.12641
Knihovny.cz E-zdroje

OBJECTIVES: Pre-exposure prophylaxis (PrEP) for HIV infection has been introduced in only a few European countries. We investigated the potential to provide PrEP in the Central and Eastern European region, and in neighbouring countries. METHODS: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was formed in February 2016 to review standards of care for HIV infection in the region. Information related to PrEP was collected through on-line surveys. Respondents were recruited by ECEE members based on their involvement in HIV care. RESULTS: Seventy-six respondents from 23 countries participated in the survey. Twenty-six (34.2%) respondents reported that PrEP [tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)] was registered by the drug registration authority in their country. Fifty-three (70.7%) respondents reported being aware of 'informal' PrEP use in their country. If they had access to PrEP, 56 (74.7%) would advise its use in their practice. Forty-five (59.2%) respondents had concerns regarding PrEP use, and 10 (13.3%) expressed the need for more training. Most of the respondents (88.2%) would provide PrEP to people with high-risk behaviours. CONCLUSIONS: PrEP is already used informally in some countries in the region. Physicians are keen to use PrEP if and when it is accessible. Obstacles towards implementing PrEP in those countries were mostly related to lack of national guidelines, drug registration and governmental strategy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028333
003      
CZ-PrNML
005      
20190822124656.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/hiv.12641 $2 doi
035    __
$a (PubMed)29989332
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kowalska, J D $u Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. Hospital for Infectious Diseases, HIV Out-Patient Clinic, Warsaw, Poland.
245    10
$a HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group / $c JD. Kowalska, D. Bursa, D. Gökengin, D. Jilich, J. Tomazic, M. Vasylyev, P. Bukovinowa, V. Mulabdic, S. Antonyak, A. Horban, ECEE Network Group,
520    9_
$a OBJECTIVES: Pre-exposure prophylaxis (PrEP) for HIV infection has been introduced in only a few European countries. We investigated the potential to provide PrEP in the Central and Eastern European region, and in neighbouring countries. METHODS: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was formed in February 2016 to review standards of care for HIV infection in the region. Information related to PrEP was collected through on-line surveys. Respondents were recruited by ECEE members based on their involvement in HIV care. RESULTS: Seventy-six respondents from 23 countries participated in the survey. Twenty-six (34.2%) respondents reported that PrEP [tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)] was registered by the drug registration authority in their country. Fifty-three (70.7%) respondents reported being aware of 'informal' PrEP use in their country. If they had access to PrEP, 56 (74.7%) would advise its use in their practice. Forty-five (59.2%) respondents had concerns regarding PrEP use, and 10 (13.3%) expressed the need for more training. Most of the respondents (88.2%) would provide PrEP to people with high-risk behaviours. CONCLUSIONS: PrEP is already used informally in some countries in the region. Physicians are keen to use PrEP if and when it is accessible. Obstacles towards implementing PrEP in those countries were mostly related to lack of national guidelines, drug registration and governmental strategy.
650    _2
$a dospělí $7 D000328
650    _2
$a emtricitabin $x terapeutické užití $7 D000068679
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HIV infekce $x prevence a kontrola $7 D015658
650    _2
$a zdravotnický personál $7 D006282
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a preexpoziční profylaxe $x metody $x statistika a číselné údaje $7 D065129
650    _2
$a bezpečný sex $7 D021841
650    _2
$a standardní péče $7 D059039
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a tenofovir $x terapeutické užití $7 D000068698
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Bursa, D $u Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. Hospital for Infectious Diseases, Warsaw, Poland.
700    1_
$a Gökengin, D $u Infectious Diseases and Clinical Microbiology, Ege University Medical Faculty, Izmir, Turkey.
700    1_
$a Jilich, D $u Department of Infectious and Tropical Diseases, Hospital Na Bulovce, Prague, Czech Republic.
700    1_
$a Tomazic, J $u Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.
700    1_
$a Vasylyev, M $u Lviv Regional Public Health Center, Lviv, Ukraine.
700    1_
$a Bukovinowa, P $u Department of Infectious Diseases and Geographical Medicine, University Hospital, Bratislava, Slovakia.
700    1_
$a Mulabdic, V $u Clinic for Infectious Diseases, Clinical Center of Sarajevo University, Sarajevo, Bosnia and Herzegovina.
700    1_
$a Antonyak, S $u Clinic of the Gromahevsky Institute of Epidemiology and Infectious Diseases, Kiev, Ukraine.
700    1_
$a Horban, A $u Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. Hospital for Infectious Diseases, HIV Out-Patient Clinic, Warsaw, Poland.
710    2_
$a ECEE Network Group
773    0_
$w MED00007240 $t HIV medicine $x 1468-1293 $g Roč. 19, č. 9 (2018), s. 629-633
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29989332 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822124935 $b ABA008
999    __
$a ok $b bmc $g 1433482 $s 1066793
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 9 $d 629-633 $e 20180710 $i 1468-1293 $m HIV medicine $n HIV Med $x MED00007240
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace